Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.579 USD | +2.30% | -0.66% | -44.56% |
Mar. 21 | Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 15 | Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 1.63M | Sales 2025 * | 13.61M | Capitalization | 4.29M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -11M | EV / Sales 2024 * | 2.63 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.32 x |
P/E ratio 2024 * |
-0.19
x | P/E ratio 2025 * |
-0.24
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.45% |
Latest transcript on Ensysce Biosciences, Inc.
1 day | +2.30% | ||
1 week | -0.66% | ||
Current month | -0.66% | ||
1 month | -24.65% | ||
3 months | -53.36% | ||
6 months | -38.14% | ||
Current year | -44.56% |
Managers | Title | Age | Since |
---|---|---|---|
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 08-12-31 |
David Humphrey
DFI | Director of Finance/CFO | 55 | 21-01-31 |
Jeffrey Millard
COO | Chief Operating Officer | 49 | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Martin
BRD | Director/Board Member | 63 | 19-12-31 |
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 08-12-31 |
Bob Gower
CHM | Chairman | 86 | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 0.5877 | +3.83% | 11 910 |
24-05-06 | 0.566 | +0.89% | 68,118 |
24-05-03 | 0.561 | -1.41% | 155,192 |
24-05-02 | 0.569 | -6.41% | 99,489 |
24-05-01 | 0.608 | +2.77% | 60,231 |
Delayed Quote Nasdaq, May 07, 2024 at 11:03 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.56% | 4.29M | |
+20.77% | 46.81B | |
-1.22% | 41.37B | |
+47.64% | 41.29B | |
-6.20% | 28.87B | |
+11.04% | 26.06B | |
-19.63% | 19.13B | |
+32.32% | 12.39B | |
+0.33% | 12.08B | |
+0.12% | 11.96B |
- Stock Market
- Equities
- ENSC Stock